Polycystic Kidney, Autosomal Dominant Clinical Trial
Official title:
Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease
The purpose of this study is to determine whether the medication pravastatin will ameliorate renal and cardiovascular disease over a 3-year period in children and young adults with autosomal dominant polycystic kidney disease (ADPKD).
Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney
disease, affecting 1 in 400 to 1000 individuals and accounting for 4% of end-stage renal
disease in the United States and 8-10% in Europe. The condition is characterized by
progressive development of kidney cysts with kidney enlargement and associated loss of kidney
function. High blood pressure and cardiovascular disease are common in patients with ADPKD.
Although the condition is often thought to affect primarily adults, it is clear that the
disease can be present in the fetus and young children.
This study was designed to determine if treatment with the medicine pravastatin can slow the
progression of kidney and heart disease when initiated early in life in patients with ADPKD.
The Investigators will assess differences between pravastatin and placebo study groups over
the three-year study period with respect to: 1) total kidney volume as assessed by magnetic
resonance imaging (MRI); 2) left ventricular mass index as assessed by MRI; 3) urinary
albumin excretion; and 4) endothelial-dependent vasodilation as assessed by brachial
ultrasound. A total of 110 subjects were enrolled in this research study. This study involved
pediatric subjects because the Investigators believe that early intervention is critical if
they are to decrease the morbidity and mortality associated with this condition. If
pravastatin is shown to be effective in ameliorating progression of renal and cardiovascular
disease in this study, routine management of people with this condition will be drastically
altered.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04310319 -
Wishing to Decrease Aquaresis in ADPKD Patients Treated With a V2Ra; the Effect of Regulating Protein and Salt
|
N/A | |
Completed |
NCT04363554 -
The Kidneys Ability to Concentrate and Dilute Urine in Patients With Autosomal Dominant Polycystic Kidney Disease
|
N/A | |
Recruiting |
NCT05521191 -
A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease
|
Phase 1 | |
Completed |
NCT03687554 -
Effect of Venglustat in Patients With Renal Impairment
|
Phase 1 | |
Terminated |
NCT03523728 -
A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients
|
Phase 2/Phase 3 | |
Completed |
NCT00565097 -
Lanreotide as Treatment of Polycystic Livers
|
Phase 2/Phase 3 | |
Completed |
NCT00410007 -
The Effect of High and Low Sodium Intake on Urinary Aquaporin-2 in Autosomal Dominant Polycystic Kidney Disease
|
N/A | |
Completed |
NCT02251275 -
Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
|
Phase 3 | |
Completed |
NCT01559363 -
A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease
|
Phase 1/Phase 2 | |
Completed |
NCT02903511 -
Feasibility Study of Metformin Therapy in ADPKD
|
Phase 2 | |
Recruiting |
NCT05510115 -
Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease
|
Phase 2 | |
Completed |
NCT02494141 -
Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKD
|
Phase 4 | |
Completed |
NCT04407481 -
PErfusioN, OxyGen ConsUmptIon and ENergetics in ADPKD (PENGUIN)
|
||
Completed |
NCT02847624 -
Post-Marketing Surveillance Study of Tolvaptan in Patients With ADPKD
|
||
Completed |
NCT03342742 -
Daily Caloric Restriction and Intermittent Fasting in Overweight and Obese Adults With Autosomal Dominant Polycystic Kidney Disease
|
N/A | |
Completed |
NCT02656017 -
Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease
|
Phase 2 | |
Completed |
NCT04023214 -
The Role of Endothelial Dysfunction in Adult Polycystic Kidney Disease
|
||
Terminated |
NCT01589705 -
The Relation Between Uric Acid Level and Endothelial Dysfunction in Patients With Polycystic Kidney Disease
|
N/A | |
Completed |
NCT00426153 -
Octreotide in Severe Polycystic Liver Disease
|
Phase 2/Phase 3 | |
Completed |
NCT04534985 -
Time Restricted Feeding in Autosomal Dominant Polycystic Kidney Disease
|
N/A |